COMMUNIQUÉS West-GlobeNewswire
-
Carbios files its 2025 Universal Registration Document
29/04/2026 -
Availabilty of 2026 AGM preparatory documents
29/04/2026 -
Communiqué de presse : Assemblée Générale Annuelle du 29 avril 2026 - Belén Garijo nommée administratrice et Directrice générale de Sanofi
29/04/2026 -
Cristcot to Present Oral Abstract at 2026 Digestive Disease Week (DDW)
29/04/2026 -
EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
29/04/2026 -
CARBIOS annonce la mise à disposition de son Document d’enregistrement universel 2025
29/04/2026 -
ORYZON to Participate in Upcoming Events in May and June
29/04/2026 -
Cronos Group Inc. to Hold Virtual 2026 Annual Meeting of Shareholders
29/04/2026 -
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
29/04/2026 -
Cannabis Growers Are Shifting Priorities: Seed Banks to Watch in 2026, According to SeedFinder.eu
29/04/2026 -
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
29/04/2026 -
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
29/04/2026 -
Inspire Medical Systems, Inc. to Present at the BofA Securities 2026 Healthcare Conference
29/04/2026 -
Ontario Building Code Review Points to a Clear Win for Families and Future Homeowners: Prevent Lung Cancer Cases by Keeping Radon Mitigation Measures in Place
29/04/2026 -
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
29/04/2026 -
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
29/04/2026 -
MindBio Files Patent Applications in 15 World Firsts
29/04/2026 -
Anika Reports First Quarter 2026 Financial Results
29/04/2026 -
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
29/04/2026
Pages